[Pharmacological and clinical profile of a new SGLT2 inhibitor, luseogliflozin (Lusefi®)].
Teisuke
T
Takahashi
Koji
K
Yamamoto
D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000494:pharmacology*; D007677:Kidney Function Tests; D011485:Protein Binding; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013012:Sorbitol / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology
D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013012:Sorbitol; C549343:1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol